Apop Biosciences
Powering cell stress detection
Apop Biosciences Pty Ltd (Apop) is an Australian biotechnology company established in October 2016 by founding director and medical researcher Assoc/Prof Peter Wookey, following decades of research into the role of the calcitonin receptor as a marker of disease. Dr Wookey’s research has been published in peer reviewed journals and presented at multiple scientific meetings.
Apop’s catchy name was inspired by the major form of Programmed Cell Death (PCD), apoptosis.
Research Reagents
Apop has launched CalRexin®:pHrodo™ Red, a first in class imaging reagent for real-time autophagy detection, enhancing our differentiated product offering to researchers and industry seeking better tools to detect and monitor cell stress processes. Apop’s proprietary antibody:fluorophore conjugates reveal novel pathways of autophagy programmed cell death in live cells and provide insights into these complex mechanisms previously unseen.
Develop Therapeutics
Apop is developing CalRexin® into a powerful delivery vehicle for therapeutics (as antibody-toxin and antibody-drug conjugates) to treat refractory tumours.
Develop Imaging Agents
Apop is developing novel CalRexin® conjugates as diagnostic tools for real time imaging of PCD in patients.
Biogenex
Molecular pathology systems
GenomeMe
IHC monoclonal antibodies
RayBiotech
Proteomic discovery tools
BBI Solutions
Diagnostic raw materials
Hillgene
Innovative products for cell and gene therapy